
  
    
      
        Background_NNP
        Tropomodulins_NNP are_VBP the_DT vertebrate_NN proteins_NNS that_WDT cap_NN the_DT
        pointed_VBD ends_NNS of_IN filamentous_JJ actin_NN [_NN 1_CD ]_NN ._. The_DT first_JJ 
        tropomodulin_NN (_( TMOD_NNP )_) gene_NN was_VBD cloned_VBN
        by_IN Sung_NNP and_CC colleagues_NNS (_( 1992_CD )_) from_IN a_DT fetal_JJ liver_NN library_NN ._.
        Three_CD additional_JJ family_NN members_NNS have_VBP been_VBN identified_VBN in_IN
        humans_NNS ,_, and_CC TMOD_NNP homologs_NNS have_VBP been_VBN identified_VBN in_IN mouse_NN ,_,
        rat_NN ,_, chick_NN ,_, 
        Drosophila_NNP ,_, and_CC 
        C_NNP ._. elegans_NNS [_NN 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD ]_NN ._.
        Expression_NNP patterns_NNS vary_VBP extensively_RB :_: 
        Tropomodulin_NNP 3_CD (_( TMOD_NNP 3_LS )_) is_VBZ ubiquitous_JJ ;_:
        
        Tropomodulin_NNP 1_CD (_( TMOD_NNP 1_LS )_) is_VBZ widespread_JJ
        in_IN heart_NN ,_, muscle_NN ,_, brain_NN ,_, lens_NN ,_, erythrocytes_NNS ,_, and_CC
        arterioles_NNS ;_: 
        Tropomodulin_NNP 2_CD (_( TMOD_NNP 2_LS )_) is_VBZ restricted_VBN
        to_TO neuronal_NN tissue_NN ;_: 
        Tropomodulin_NNP 4_CD (_( TMOD_NNP 4_LS )_) ._. is_VBZ expressed_VBN
        in_IN skeletal_NN muscle_NN ,_, with_IN a_DT less_RBR abundant_JJ ~_NN 7_CD kb_NN transcript_NN
        expressed_VBD in_IN both_DT skeletal_NN and_CC cardiac_JJ muscle_NN [_NN 8_CD ]_NN ._.
        Whereas_IN tropomodulins_NNS or_CC the_DT Arp_NNP 2_CD /_NN 3_CD complex_JJ cap_NN the_DT
        pointed_VBN end_NN of_IN actin_NN filaments_NNS ,_, the_DT barbed_VBN end_NN can_MD be_VB
        capped_VBN by_IN CapZ_NNP ,_, α_NN ,_, β_NN ,_, and_CC γ_NN adducins_NNS as_RB well_RB as_IN gelsolin_NN [_NN
        9_CD 10_CD 11_CD ]_NN ._. Control_NNP of_IN thin_JJ filament_NN length_NN is_VBZ critical_JJ for_IN
        maintaining_VBG proper_JJ sarcomere_NN function_NN and_CC length_NN [_NN 12_CD ]_NN ._.
        Inhibition_NNP of_IN Tmod_NNP 1_CD 's_POS capping_VBG activity_NN -_: either_CC by_IN using_VBG an_DT
        antibody_NN to_TO its_PRP$ C-_NNP terminal_NN end_NN or_CC by_IN decreasing_VBG expression_NN
        using_VBG an_DT antisense_NN 
        Tmod_NNP 1_CD transcript_NN -_: results_NNS in_IN
        elongated_JJ thin_JJ filaments_NNS and_CC decreased_VBD cardiac_JJ
        contractility_NN [_NN 13_CD 14_CD ]_NN ._. 
        Tmod_NNP 1_CD overexpression_NN in_IN rat_NN
        cardiomyocytes_NNS causes_NNS shortening_NN of_IN the_DT thin_JJ filaments_NNS and_CC
        sarcomere_NN disorganization_NN ,_, resulting_VBG in_IN myofibril_NN
        degeneration_NN [_NN 14_CD ]_NN ._. Likewise_RB ,_, mice_NNS overexpressing_VBG 
        TMOD_NNP 1_CD in_IN the_DT heart_NN show_NN disrupted_VBD
        sarcomere_NN organization_NN with_IN shortened_VBN thin_JJ filaments_NNS ,_,
        leading_VBG to_TO myofibril_NN degeneration_NN and_CC dilated_JJ
        cardiomyopathy_NN [_NN 15_CD ]_NN ._. Recently_RB ,_, Littlefield_NNP and_CC
        colleagues_NNS showed_VBD that_DT overexpression_NN of_IN GFP-Tmod_NNP 1_CD in_IN chick_NN
        cardiac_JJ myocytes_NNS results_NNS in_IN shortening_NN of_IN thin_JJ filaments_NNS ;_:
        the_DT authors_NNS proposed_VBN that_IN excess_JJ Tmod_NNP 1_CD decreases_NNS the_DT
        affinity_NN between_IN actin_NN monomers_NNS and_CC pointed_VBD ends_VBZ ,_, leading_VBG
        to_TO monomer_NN dissociation_NN and_CC filament_NN shortening_VBG [_NN 42_CD ]_NN ._.
        Mutations_NNP in_IN many_JJ proteins_NNS making_VBG up_RP the_DT cardiac_JJ sarcomere_NN
        have_VBP been_VBN shown_VBN to_TO cause_VB cardiac_JJ hypertrophy_NN [_NN 16_CD 17_CD 18_CD 19_CD
        ]_NN :_: mutations_NNS in_IN the_DT 
        TPM_NNP 1_CD gene_NN ,_, for_IN example_NN ,_, cause_VB type_NN 3_CD
        familial_NN hypertrophic_JJ cardiomyopathy_NN (_( CMH_NNP 3_LS )_) ,_, and_CC a_DT
        transgenic_JJ mouse_NN expressing_VBG a_DT CMH_NNP 3_CD mutation_NN develops_VBZ
        ventricular_NN myocyte_NN disarray_NN and_CC hypertrophy_NN [_NN 20_CD ]_NN ._.
        Mutations_NNP in_IN myosin_NN heavy_JJ chain_NN 7_CD are_VBP estimated_VBN to_TO account_VB
        for_IN 40_CD -_: 50_CD %_NN of_IN the_DT cases_NNS of_IN hypertrophic_JJ cardiomyopathy_NN [_NN 21_CD
        ]_NN ._.
        Given_VBN the_DT importance_NN of_IN actin-binding_JJ proteins_NNS in_IN human_JJ
        disease_NN ,_, we_PRP mapped_VBN 
        TMOD_NNP 2_CD and_CC 
        TMOD_NNP 4_CD and_CC found_VBD them_PRP to_TO localize_NN to_TO
        15_CD q_NN 21_CD ._. 1_LS and_CC 1_CD q_NN 12_CD ,_, respectively_RB [_NN 8_CD ]_NN ._. These_DT loci_NN overlap_VB
        with_IN the_DT genomic_JJ regions_NNS containing_VBG the_DT genes_NNS for_IN
        amyotrophic_JJ lateral_NN sclerosis_NN 5_CD (_( ALS_NNP 5_LS )_) and_CC limb_NN girdle_NN
        muscular_JJ dystrophy_NN 1_CD B_NNP (_( LGMD_NNP 1_CD B_NNP )_) ,_, respectively_RB [_NN 22_CD 23_CD ]_NN ._. We_PRP
        characterized_VBD these_DT tropomodulin_NN genomic_JJ loci_NN for_IN use_NN in_IN
        mutational_NN analysis_NN ._. During_IN the_DT course_NN of_IN this_DT study_NN ,_, the_DT
        gene_NN mutated_VBN in_IN LGMD_NNP 1_CD B_NNP was_VBD identified_VBN as_IN Lamin_NNP A_DT /_NN C_NNP [_NN 24_CD ]_NN ._.
        Our_PRP$ investigation_NN ,_, however_RB ,_, revealed_VBD that_IN an_DT unrelated_JJ
        gene_NN ,_, 
        YL-_NNP 1_CD ,_, intergenically_RB spliced_JJ into_IN 
        TMOD_NNP 4_CD ._. YL-_NNP 1_CD is_VBZ a_DT putative_JJ
        transformation_NN suppressor_NN gene_NN that_IN localizes_NNS to_TO the_DT
        nucleus_NN and_CC binds_NNS to_TO DNA_NNP [_NN 25_CD 26_CD ]_NN ._. 
        YL-_NNP 1_CD is_VBZ organized_VBN into_IN six_CD exons_NNS and_CC
        produces_VBZ several_JJ alternatively_RB spliced_JJ transcripts_NNS using_VBG
        both_DT intergenic_JJ and_CC cryptic_JJ splicing_VBG ._. This_DT relationship_NN
        between_IN 
        YL-_NNP 1_CD and_CC 
        TMOD_NNP 4_CD serves_VBZ as_IN yet_RB another_DT example_NN
        of_IN the_DT complexity_NN of_IN genomic_JJ organization_NN and_CC gene_NN
        regulation_NN ._.
      
      
        Results_NNS
        
          Genomic_NNP organization_NN of_IN TMOD_NNP 2_CD ,_, TMOD_NNP 4_CD ,_, and_CC
          YL-_NNP 1_CD
          We_PRP determined_VBD the_DT exon_NN /_NN intron_NN boundaries_NNS of_IN 
          TMOD_NNP 2_CD and_CC 
          TMOD_NNP 4_CD by_IN sequencing_VBG PCR_NNP products_NNS
          amplified_VBN from_IN primers_NNS within_IN adjacent_JJ exons_NNS ,_, and_CC
          sequencing_VBG short_JJ exon_NN containing_VBG genomic_JJ fragments_NNS ._. We_PRP
          identified_VBD nine_CD coding_VBG exons_NNS in_IN 
          TMOD_NNP 2_CD and_CC in_IN 
          TMOD_NNP 4_CD which_WDT are_VBP spread_VBN over_IN a_DT 45_CD kb_NN
          and_CC 4_CD ._. 7_CD kb_NN genomic_JJ region_NN ,_, respectively_RB (_( Fig_NNP ._. 1_LS )_) ._. The_DT
          exon_NN /_NN intron_NN boundaries_NNS of_IN the_DT two_CD genes_NNS are_VBP conserved_JJ ,_,
          except_IN that_DT 
          TMOD_NNP 2_CD has_VBZ more_JJR 5_CD '_POS untranslated_JJ
          region_NN (_( UTR_NNP )_) in_IN coding_VBG exon_NN 1_CD and_CC more_JJR 
          3_CD '_POS UTR_NNP in_IN exon_NN 9_CD than_IN 
          TMOD_NNP 4_CD ._. TMOD_NNP 2_CD and_CC TMOD_NNP 4_CD also_RB contain_VB
          additional_JJ 5_CD '_POS UTR_NNP exons_NNS ._. Our_PRP$ reported_JJ cDNAs_NNS have_VBP 69_CD and_CC
          19_CD bp_NN additional_JJ sequence_NN 5_CD '_POS to_TO what_WP is_VBZ contained_VBN in_IN exon_NN
          1_CD for_IN each_DT gene_NN ,_, respectively_RB [_NN 8_CD ]_NN ._. A_DT search_NN of_IN the_DT EST_NNP
          database_NN using_VBG the_DT 
          TMOD_NNP 4_CD 5_CD '_POS end_NN extended_VBD this_DT sequence_NN
          by_IN 8_CD bp_NN (_( ESTs_NNP AA_NN 194560_CD ,_, AA_NN 192772_CD ,_, and_CC AA_NN 178988_CD )_) ._. We_PRP were_VBD
          able_JJ to_TO align_VBP this_DT sequence_NN and_CC found_VBD that_IN it_PRP lies_VBZ 1006_CD
          bp_NN from_IN 
          TMOD_NNP 4_CD exon_NN 1_CD and_CC contained_VBD a_DT
          consensus_NN donor_NN splice_NN site_NN ._. Using_VBG 5_CD '_POS rapid_JJ amplification_NN
          of_IN cDNA_NN ends_VBZ (_( RACE_NNP )_) from_IN 
          TMOD_NNP 4_CD exon_NN 2_CD ,_, we_PRP discovered_VBD that_IN
          this_DT exon_NN was_VBD 93_CD bp_NN in_IN length_NN and_CC contained_VBD no_DT consensus_NN
          AG_NNP acceptor_NN ._. 3_LS '_POS RACE_NNP from_IN 
          TMOD_NNP 4_CD exon_NN 2_CD extended_VBN our_PRP$ reported_JJ
          cDNA_NN by_IN an_DT additional_JJ 9_CD bp_NN ,_, bringing_VBG the_DT entire_JJ length_NN of_IN
          the_DT 
          TMOD_NNP 4_CD transcript_NN to_TO 1_CD ._. 267_CD kb_NN
          (_( Genbank_NNP Accession_NNP #_# AF_NNP 393374_CD )_) ._.
          Using_VBG the_DT 5_CD '_POS end_NN of_IN the_DT 
          TMOD_NNP 2_CD cDNA_NN ,_, we_PRP searched_VBD the_DT high_JJ
          throughput_NN genomic_JJ sequences_NNS (_( HTGS_NNP )_) database_NN and_CC
          identified_VBD a_DT sequence_NN ,_, NT_NNP 010204_CD ,_, that_WDT contained_VBD 100_CD %_NN
          identity_NN to_TO the_DT 69_CD basepairs_NNS of_IN 
          TMOD_NNP 2_CD 5_CD '_POS UTR_NNP and_CC contained_VBD a_DT
          consensus_NN GT_NNP donor_NN splice_NN site_NN ._. The_DT distance_NN from_IN this_DT
          UTR_NNP exon_NN to_TO coding_VBG exon_NN 1_CD is_VBZ 14_CD ._. 6_CD kb_NN ,_, but_CC the_DT sequence_NN is_VBZ
          not_RB completely_RB ordered_VBD ._. Using_VBG nomenclature_NN from_IN previous_JJ
          tropomodulin_NN genes_NNS we_PRP designated_VBN these_DT 5_CD '_POS UTR_NNP exons_NNS as_IN E_NNP 0_CD
          [_NN 27_CD ]_NN ._.
          We_PRP sought_VBD to_TO determine_VB the_DT genomic_JJ structure_NN of_IN 
          YL-_NNP 1_CD when_WRB we_PRP discovered_VBD that_IN it_PRP
          lies_VBZ next_JJ to_TO and_CC intergenically_RB splices_NNS into_IN 
          TMOD_NNP 4_CD (_( see_VB below_IN )_) ._. Using_VBG the_DT same_JJ
          methods_NNS described_VBD above_IN ,_, we_PRP identified_VBD six_CD coding_VBG exons_NNS
          of_IN 
          YL-_NNP 1_CD spanning_VBG 14_CD ._. 2_LS kb_NN (_( Fig_NNP ._. 1_LS )_) ._. The_DT
          distance_NN from_IN the_DT last_JJ exon_NN of_IN 
          YL-_NNP 1_CD to_TO E_NNP 0_CD 
          TMOD_NNP 4_CD is_VBZ 291_CD bp_NN ._. We_PRP sequenced_JJ the_DT
          entire_JJ genomic_JJ region_NN encompassing_VBG 
          TMOD_NNP 4_CD from_IN the_DT end_NN of_IN 
          YL-_NNP 1_CD exon_NN 6_CD through_IN 
          TMOD_NNP 4_CD exon_NN 9_CD and_CC deposited_VBD it_PRP in_IN
          Genbank_NNP (_( Accession_NNP No_UH ._. AF_NNP 393375_CD )_) ._. The_DT sizes_NNS of_IN the_DT exons_NNS
          and_CC introns_NNS as_RB well_RB as_IN the_DT boundary_NN sequences_NNS for_IN 
          TMOD_NNP 2_CD ,_, TMOD_NNP 4_CD ,_, and_CC 
          YL-_NNP 1_CD are_VBP provided_VBN (_( See_VB Table_NNP 1_LS )_) ._.
          Consensus_NNP splice_NN sites_NNS were_VBD identified_VBN for_IN all_DT 
          Tropomodulin_NNP exons_NNS ,_, but_CC 
          YL-_NNP 1_CD exon_NN 1_CD contained_VBD a_DT GC_NNP 5_CD '_POS
          splice_NN site_NN instead_RB of_IN the_DT more_RBR common_JJ GT_NNP 5_CD '_POS splice_NN site_NN ._.
          This_DT splice_NN site_NN also_RB conforms_VBZ well_RB to_TO other_JJ nonconsensus_JJ
          GC_NNP 5_CD '_POS splice_NN sites_NNS as_IN described_VBN in_IN Mount_NNP (_( 2000_CD )_) with_IN a_DT G_NNP
          at_IN the_DT -_: 1_CD and_CC +_NN 5_CD positions_NNS [_NN 28_CD ]_NN ._. We_PRP used_VBD the_DT very_RB 3_CD '_POS
          end_NN of_IN the_DT 
          YL-_NNP 1_CD cDNA_NN to_TO look_VB for_IN additional_JJ 3_CD '_POS
          UTR_NNP ._. We_PRP identified_VBD three_CD ESTs_NNP (_( ESTs_NNP AA_NN 128103_CD ,_, AW_NNP 627363_CD ,_,
          and_CC AI_NNP 591193_CD )_) that_WDT were_VBD identical_JJ at_IN the_DT 
          3_CD '_POS end_NN and_CC extended_VBD the_DT reported_VBD
          UTR_NNP by_IN an_DT additional_JJ 150_CD bp_NN ._.
        
        
          Mutational_NNP Analysis_NNP of_IN TMOD_NNP 2_CD in_IN ALS_NNP 5_CD
          Two_CD patients_NNS and_CC two_CD controls_NNS from_IN a_DT family_NN with_IN an_DT
          autosomal_NN recessive_JJ form_NN of_IN familial_NN ALS_NNP (_( ALS_NNP 5_LS )_) were_VBD
          analyzed_VBN for_IN mutations_NNS in_IN 
          TMOD_NNP 2_CD ._. We_PRP amplified_VBN coding_VBG exons_NNS
          1_CD -_: 9_CD using_VBG primers_NNS flanking_VBG each_DT exon_NN (_( See_VB Table_NNP 2_LS )_) ._. These_DT
          PCR_NNP products_NNS were_VBD sequenced_JJ to_TO identify_VB any_DT potential_JJ
          point_NN mutations_NNS or_CC small_JJ deletions_NNS ._. We_PRP did_VBD not_RB detect_VB any_DT
          mutations_NNS or_CC polymorphisms_NNS in_IN any_DT of_IN the_DT patients_NNS or_CC
          controls_NNS ._.
        
        
          Inter_NNP genic_JJ splicing_VBG of_IN YL-_NNP 1_CD into_IN TMOD_NNP 4_CD
          During_IN our_PRP$ analysis_NN of_IN 
          TMOD_NNP 4_CD 's_POS genomic_JJ structure_NN we_PRP
          identified_VBD EST_NNP AI_NNP 763406_CD ,_, which_WDT contains_VBZ 
          TMOD_NNP 4_CD exon_NN 9_CD and_CC part_NN of_IN the_DT coding_VBG
          region_NN of_IN another_DT unrelated_JJ gene_NN known_VBN as_IN 
          YL-_NNP 1_CD ._. Using_VBG 5_CD '_POS RACE_NNP we_PRP were_VBD able_JJ to_TO
          confirm_VB the_DT presence_NN of_IN this_DT transcript_NN and_CC identify_VB
          other_JJ unique_JJ intergenic_JJ RACE_NNP products_NNS ._. Figure_NN 2_CD summarizes_NNS
          our_PRP$ findings_NNS ._. There_EX are_VBP two_CD main_JJ intergenic_JJ products_NNS ,_,
          each_DT of_IN which_WDT was_VBD represented_VBN multiple_JJ times_NNS in_IN our_PRP$ RACE_NNP
          clones_NNS ._. The_DT first_JJ intergenic_JJ splice_NN products_NNS (_( RACE_NNP #_# 9_CD -_: 11_CD ,_,
          and_CC 13_CD -_: 15_CD )_) are_VBP similar_JJ to_TO EST_NNP AI_NNP 763406_CD ._. These_DT variants_NNS
          consist_VBP of_IN 
          YL-_NNP 1_CD exons_NNS 1_CD -_: 5_CD ,_, and_CC 
          TMOD_NNP 4_CD exon_NN 9_CD ._. The_DT ORF_NNP of_IN this_DT
          splice_NN variant_NN keeps_VBZ the_DT reading_NN frame_NN of_IN 
          YL-_NNP 1_CD but_CC changes_VBZ the_DT 
          TMOD_NNP 4_CD endogenous_JJ reading_NN frame_NN to_TO
          make_VB the_DT reading_NN frame_NN of_IN exon_NN 9_CD completely_RB open_JJ ._.
          Translation_NN of_IN this_DT ORF_NNP would_MD theoretically_RB produce_VB a_DT
          protein_NN of_IN at_IN least_JJS 271_CD amino_JJ acids_NNS containing_VBG the_DT amino_JJ
          terminal_NN half_NN of_IN 
          YL-_NNP 1_CD but_CC a_DT unique_JJ carboxy_NN terminus_JJ ._.
          If_IN ,_, however_RB ,_, we_PRP extend_VBP the_DT sequence_NN to_TO include_VB intronic_JJ
          sequence_NN downstream_JJ of_IN exon_NN 9_CD ,_, we_PRP discover_VBP that_IN the_DT frame_NN
          is_VBZ kept_VBN open_VB an_DT additional_JJ 45_CD bp_NN ,_, making_VBG this_DT theoretical_JJ
          protein_NN 286_CD amino_JJ acids_NNS in_IN length_NN ._. Using_VBG primers_NNS to_TO exon_NN
          1_CD of_IN 
          YL-_NNP 1_CD and_CC exon_NN 9_CD of_IN 
          TMOD_NNP 4_CD ,_, we_PRP confirmed_VBD the_DT presence_NN of_IN
          this_DT intergenic_JJ product_NN by_IN RT-PCR_NNP on_IN human_JJ heart_NN RNA_NNP ._.
          RACE_NNP product_NN #_# 12_CD was_VBD similar_JJ to_TO RACE_NNP products_NNS #_# 9_CD -_: 11_CD ,_,
          13_CD -_: 15_CD except_IN that_DT 
          YL-_NNP 1_CD splices_NNS from_IN exon_NN 5_CD to_TO 
          TMOD_NNP 4_CD exon_NN 8_CD which_WDT then_RB splices_NNS to_TO
          exon_NN 9_CD (_( Fig_NNP ._. 2_LS )_) ._. This_DT produces_VBZ an_DT ORF_NNP coding_VBG for_IN a_DT 252_CD
          amino_JJ acid_NN protein_NN that_IN changes_VBZ the_DT frame_NN of_IN 
          TMOD_NNP 4_CD ,_, adding_VBG only_RB 16_CD additional_JJ
          amino_JJ acids_NNS before_IN encountering_VBG a_DT stop_NN codon_NN ._. Another_DT set_NN
          of_IN RACE_NNP products_NNS (_( RACE_NNP #_# 1_CD -_: 5_LS )_) consists_VBZ of_IN 
          YL-_NNP 1_CD exons_NNS 4_CD and_CC 5_CD and_CC 
          TMOD_NNP 4_CD exons_NNS 1_CD -_: 9_CD ,_, except_IN that_DT exon_NN 2_CD
          uses_VBZ an_DT internal_JJ consensus_NN cryptic_JJ splice_NN site_NN ._. Using_VBG the_DT
          
          YL-_NNP 1_CD endogenous_JJ frame_NN we_PRP find_VBP that_IN
          this_DT ORF_NNP terminates_NNS in_IN 
          TMOD_NNP 4_CD exon_NN 1_CD ._. If_IN we_PRP assume_VBP an_DT ORF_NNP
          including_VBG 
          YL-_NNP 1_CD exons_NNS 1_CD -_: 3_CD along_IN with_IN the_DT
          isolated_VBN RACE_NNP product_NN ,_, then_RB it_PRP would_MD theoretically_RB
          produce_VB a_DT protein_NN of_IN 264_CD amino_JJ acids_NNS ._. We_PRP used_VBD the_DT
          translated_VBN protein_NN sequences_NNS from_IN these_DT intergenic_JJ ORFs_NNP
          and_CC analyzed_VBD them_PRP using_VBG InterPro_NNP Scan_NNP via_IN EXPASY_NNP ._. No_DT
          additional_JJ sequence_NN motifs_NNS or_CC domains_NNS were_VBD identified_VBN ._.
          Another_DT type_NN of_IN RACE_NNP product_NN we_PRP identified_VBD (_( RACE_NNP #_# 26_CD -_: 31_CD )_)
          is_VBZ the_DT incompletely_RB spliced_JJ products_NNS of_IN 
          TMOD_NNP 4_CD ._. In_IN no_DT case_NN did_VBD we_PRP observe_VB
          the_DT inclusion_NN of_IN 
          YL-_NNP 1_CD exon_NN 6_CD or_CC the_DT use_NN of_IN the_DT
          normal_JJ splice_NN acceptor_NN of_IN 
          TMOD_NNP 4_CD exon_NN 2_CD -_: the_DT cryptic_JJ splice_NN
          acceptor_NN was_VBD always_RB present_JJ in_IN intergenic_JJ RACE_NNP products_NNS ._.
          Furthermore_RB ,_, the_DT YL-_NNP 1_CD alpha_NN helical_JJ domain_NN ,_, which_WDT is_VBZ
          thought_VBN to_TO contain_VB the_DT DNA_NNP binding_JJ domain_NN ,_, is_VBZ maintained_VBN
          in_IN all_DT intergenic_JJ splice_NN products_NNS contained_VBD within_IN 
          YL-_NNP 1_CD exons_NNS 4_CD and_CC 5_CD ._.
        
        
          YL-_NNP 1_CD intraexonic_JJ spliced_JJ transcripts_NNS and_CC expression_NN
          pattern_NN
          To_TO better_JJR understand_VB the_DT nature_NN of_IN 
          YL-_NNP 1_CD 's_POS intergenic_JJ splicing_VBG ,_, we_PRP
          searched_VBD the_DT EST_NNP database_NN for_IN other_JJ alternative_NN and_CC
          intergenic_JJ 
          YL-_NNP 1_CD transcripts_NNS ._. Using_VBG either_CC the_DT 
          YL-_NNP 1_CD or_CC 
          TMOD_NNP 4_CD cDNAs_NNS in_IN a_DT BLAST_NN search_NN of_IN
          the_DT human_JJ EST_NNP database_NN ,_, we_PRP were_VBD unable_JJ to_TO identify_VB any_DT
          additional_JJ intergenic_JJ transcripts_NNS ,_, but_CC we_PRP did_VBD uncover_VB
          several_JJ 
          YL-_NNP 1_CD ESTs_NNP that_WDT had_VBD apparently_RB
          spliced_JJ within_IN exons_NNS in_IN such_JJ a_DT way_NN as_IN to_TO not_RB use_VB the_DT
          canonical_JJ consensus_NN splice_NN acceptors_NNS or_CC donors_NNS ,_, the_DT rarer_NN
          GC_NNP or_CC AT_NNP donor_NN sites_NNS or_CC the_DT AC_NNP acceptor_NN site_NN [_NN 29_CD ]_NN ._.
          ESTs_NNP AI_NNP 560960_CD and_CC AI_NNP 369608_CD were_VBD identical_JJ and_CC contained_VBD 
          YL-_NNP 1_CD exons_NNS 1_CD and_CC 2_CD but_CC splice_NN
          within_IN exon_NN 2_CD at_IN position_NN 276_CD (_( position_NN is_VBZ in_IN bp_NN relative_JJ
          to_TO Genbank_NNP sequence_NN D_NNP 43642_CD )_) to_TO position_VB 1107_CD (_( internal_JJ to_TO
          exon_NN 6_CD )_) (_( Fig_NNP ._. 3_LS )_) ._. Translation_NN of_IN this_DT ORF_NNP would_MD produce_VB a_DT
          truncated_JJ protein_NN of_IN only_RB 121_CD amino_JJ acids_NNS ._. EST_NNP AI_NNP 560960_CD
          was_VBD obtained_VBN from_IN the_DT IMAGE_NNP consortium_NN and_CC sequenced_JJ ._. It_PRP
          is_VBZ 476_CD bp_NN in_IN length_NN and_CC contains_VBZ 
          YL-_NNP 1_CD exons_NNS 1_CD and_CC up_IN to_TO position_VB 276_CD
          in_IN exon_NN 2_CD at_IN which_WDT it_PRP splices_NNS internal_JJ to_TO exon_NN 6_CD at_IN
          position_NN 1107_CD ._. A_DT second_JJ splice_NN product_NN was_VBD represented_VBN by_IN
          ESTs_NNP AI_NNP 366716_CD and_CC AW_NNP 005187_CD ,_, in_IN which_WDT the_DT sequence_NN appears_VBZ
          to_TO splice_NN from_IN position_NN 113_CD in_IN exon_NN 1_CD to_TO exon_NN 6_CD at_IN
          position_NN 936_CD (_( Fig_NNP ._. 3_LS )_) ._. This_DT would_MD produce_VB another_DT
          truncated_JJ protein_NN that_WDT is_VBZ 89_CD amino_JJ acids_NNS in_IN length_NN ._.
          Another_DT unusual_JJ splice_NN product_NN was_VBD represented_VBN by_IN ESTs_NNP
          AA_NN 443950_CD and_CC AA_NN 653180_CD ._. These_DT ESTs_NNP demonstrate_VB splicing_VBG
          within_IN 
          YL-_NNP 1_CD exon_NN six_CD itself_PRP ,_, from_IN position_NN
          936_CD to_TO 1062_CD (_( skipping_VBG over_IN ~_NN 126_CD bp_NN )_) ,_, changing_VBG the_DT frame_NN
          and_CC making_VBG it_PRP open_JJ past_JJ the_DT endogenous_JJ stop_NN codon_NN (_( Fig_NNP ._.
          3_LS )_) ._. EST_NN AA_NN 443950_CD was_VBD obtained_VBN from_IN the_DT image_NN consortium_NN
          and_CC sequenced_JJ ._. It_PRP contained_VBD a_DT 1199_CD bp_NN insert_NN which_WDT
          contained_VBD all_DT of_IN 
          YL-_NNP 1_CD exons_NNS 1_CD -_: 5_CD and_CC exon_NN six_CD as_IN
          described_VBN above_IN and_CC encodes_NNS an_DT ORF_NNP for_IN a_DT 358_CD amino_JJ acid_NN
          protein_NN ._. However_RB ,_, EST_NNP AA_NN 653180_CD has_VBZ an_DT additional_JJ six_CD base_NN
          pairs_NNS at_IN the_DT splice_NN junction_NN site_NN coding_VBG for_IN leucine_NN and_CC
          proline_NN ,_, suggesting_VBG that_IN either_DT the_DT site_NN produces_VBZ two_CD
          different_JJ splice_NN variants_NNS or_CC there_EX is_VBZ some_DT type_NN of_IN
          intermediate_JJ stage_NN of_IN splicing_VBG at_IN this_DT site_NN ._. In_IN either_DT
          case_NN ,_, the_DT protein_NN produced_VBN from_IN this_DT ORF_NNP (_( if_IN AA_NN 653180_CD
          contains_VBZ the_DT rest_NN of_IN the_DT intact_JJ 5_CD '_POS 
          YL-_NNP 1_CD transcript_NN )_) would_MD be_VB 360_CD amino_JJ
          acids_NNS ._. This_DT truncates_NNS the_DT reported_VBD 
          YL-_NNP 1_CD protein_NN only_RB by_IN 6_CD or_CC 4_CD amino_JJ
          acids_NNS ._. Using_VBG InterPro_NNP Scan_NNP via_IN EXPASY_NNP ,_, we_PRP determined_VBD that_IN
          these_DT few_JJ amino_JJ acids_NNS do_VBP not_RB produce_VB any_DT potential_JJ
          phosphorylation_NN sites_NNS or_CC protein_NN domains_NNS or_CC motifs_NNS ._. Two_CD
          of_IN these_DT three_CD splice_NN variants_NNS use_VBP the_DT 936_CD position_NN for_IN
          splicing_VBG as_IN a_DT putative_JJ donor_NN in_IN one_CD case_NN and_CC as_IN an_DT
          acceptor_NN in_IN the_DT other_JJ ._. We_PRP cannot_NN explain_VBP this_DT finding_NN ,_,
          but_CC it_PRP may_MD suggest_VB that_IN 
          YL-_NNP 1_CD undergoes_NNS a_DT great_JJ degree_NN of_IN
          intraexonic_JJ splicing_VBG ._. This_DT high_JJ degree_NN of_IN splicing_VBG
          together_RB with_IN the_DT lack_NN of_IN a_DT GT_NNP donor_NN site_NN in_IN the_DT last_JJ
          exon_NN ,_, and_CC the_DT close_JJ proximity_NN of_IN 
          YL-_NNP 1_CD and_CC 
          TMOD_NNP 4_CD ,_, may_MD account_VB for_IN the_DT
          intergenic_JJ splicing_VBG between_IN these_DT genes_NNS ._.
          We_PRP also_RB wanted_VBD to_TO determine_VB whether_IN the_DT 
          YL-_NNP 1_CD expression_NN pattern_NN overlapped_JJ
          with_IN 
          TMOD_NNP 4_CD ._. A_DT human_JJ multiple_JJ tissue_NN
          Northern_NNP blot_NN was_VBD probed_JJ with_IN a_DT 
          YL-_NNP 1_CD RT-PCR_NNP product_NN revealing_VBG a_DT
          single_JJ 1_CD ._. 4_CD -_: 1_CD ._. 6_CD kb_NN band_NN in_IN all_DT lanes_NNS (_( Fig_NNP ._. 4_LS )_) ._. This_DT is_VBZ
          consistent_JJ with_IN the_DT reported_VBN ubiquitous_JJ expression_NN of_IN 
          YL-_NNP 1_CD in_IN the_DT rat_NN [_NN 25_CD ]_NN ._.
        
      
      
        Discussion_NNP
        Sequencing_NNP PCR_NNP fragments_NNS and_CC genomic_JJ subclones_NNS from_IN
        phage_NN artificial_JJ chromosomes_NNS (_( PACs_NNPS )_) and_CC bacterial_JJ
        artificial_JJ chromosomes_NNS (_( BACs_NNP )_) that_WDT 
        contain_VBP TMOD_NNP 2_CD and_CC 
        TMOD_NNP 4_CD allowed_VBN us_PRP to_TO determine_VB the_DT
        genomic_JJ structure_NN of_IN these_DT two_CD 
        Tropomodulin_NNP genes_NNS ._. Although_IN
        mutational_NN analysis_NN of_IN the_DT coding_VBG region_NN of_IN 
        TMOD_NNP 2_CD in_IN ALS_NNP 5_CD and_CC 
        TMOD_NNP 4_CD in_IN LGMD_NNP 1_CD B_NNP patients_NNS failed_VBD to_TO
        reveal_VB any_DT point_NN mutations_NNS ,_, small_JJ deletions_NNS ,_, or_CC
        polymorphisms_NNS ,_, we_PRP did_VBD find_VB that_IN 
        TMOD_NNP 2_CD and_CC 
        TMOD_NNP 4_CD consist_VBP of_IN nine_CD coding_VBG exons_NNS
        and_CC at_IN least_JJS one_CD 5_CD '_POS untranslated_JJ exon_NN (_( E_NNP 0_CD )_) ._.
        This_DT is_VBZ identical_JJ to_TO the_DT genomic_JJ structure_NN reported_VBD for_IN 
        TMOD_NNP 1_CD and_CC 
        Tmod_NNP 1_CD by_IN Chu_NNP and_CC colleagues_NNS and_CC
        Conley_NNP et_CC al_NN ._. [_NN 27_CD 41_CD ]_NN ._. In_IN addition_NN ,_, they_PRP identified_VBD an_DT
        86_CD bp_NN 5_CD '_POS UTR_NNP exon_NN which_WDT was_VBD expressed_VBN in_IN a_DT tissue-specific_JJ
        manner_NN ._. We_PRP performed_VBD 5_CD '_POS RACE_NNP for_IN 
        TMOD_NNP 4_CD and_CC identified_VBN only_RB a_DT single_JJ 93_CD
        bp_NN 5_CD '_POS UTR_NNP exon_NN (_( E_NNP 0_CD )_) which_WDT lies_VBZ 1006_CD bp_NN from_IN coding_VBG exon_NN 1_CD ._.
        We_PRP did_VBD not_RB examine_VB whether_IN the_DT E_NNP 0_CD exons_NNS of_IN 
        TMOD_NNP 2_CD and_CC 
        TMOD_NNP 4_CD were_VBD expressed_VBN in_IN a_DT
        tissue-specific_JJ manner_NN ._. In_IN addition_NN ,_, the_DT 
        TMOD_NNP 2_CD transcript_NN is_VBZ approximately_RB
        9_CD ._. 5_CD -_: 10_CD kb_NN in_IN length_NN and_CC our_PRP$ reported_JJ cDNA_NN only_RB accounts_VBZ for_IN
        2_CD ._. 47_CD kb_NN [_NN 8_CD ]_NN ._. Therefore_RB ,_, there_EX are_VBP additional_JJ UTR_NNP exons_NNS
        or_CC sequence_NN that_IN we_PRP have_VBP not_RB identified_VBN in_IN this_DT study_NN ._. This_DT
        may_MD not_RB be_VB the_DT case_NN for_IN 
        TMOD_NNP 4_CD ,_, because_IN our_PRP$ reported_JJ cDNA_NN in_IN
        addition_NN to_TO the_DT 93_CD base_NN pairs_NNS from_IN the_DT E_NNP 0_CD sequence_NN and_CC the_DT
        additional_JJ 9_CD bp_NN from_IN the_DT 3_CD '_POS end_NN produces_VBZ a_DT transcript_NN of_IN
        the_DT same_JJ size_NN as_IN the_DT major_JJ transcript_NN seen_VBN by_IN Northern_NNP ._.
        However_RB ,_, the_DT larger_JJR transcripts_NNS (_( 2_CD ._. 4_LS and_CC 3_CD ._. 0_CD kb_NN )_) seen_VBN on_IN
        Northern_NNP may_MD contain_VB additional_JJ sequence_NN that_IN we_PRP were_VBD
        unable_JJ to_TO identify_VB in_IN this_DT study_NN ,_, or_CC may_MD represent_VB
        incompletely_RB spliced_JJ transcripts_NNS ._.
        EST_NN database_NN searches_NNS in_IN conjunction_NN with_IN the_DT 
        YL-_NNP 1_CD genomic_JJ structure_NN allowed_VBD us_PRP to_TO
        identify_VB three_CD unique_JJ intraexonic_JJ splicing_VBG events_NNS ._. Two_CD of_IN
        the_DT three_CD events_NNS theoretically_RB would_MD produce_VB truncated_JJ
        proteins_NNS with_IN little_JJ similarity_NN to_TO the_DT normal_JJ protein_NN ._.
        These_DT splicing_VBG events_NNS do_VBP not_RB use_VB the_DT canonical_JJ AG_NNP and_CC GT_NNP
        splice_NN sites_NNS ,_, nor_CC do_VBP they_PRP use_VBP the_DT rarer_NN GC_NNP ,_, AT_NNP ,_, or_CC AC_NNP
        splice_NN sites_NNS ._. This_DT may_MD represent_VB yet_RB another_DT form_NN of_IN
        splicing_VBG for_IN the_DT creation_NN of_IN unique_JJ transcripts_NNS and_CC ,_, or_CC
        gene_NN regulation_NN ._.
        We_PRP also_RB identified_VBD two_CD intergenic_JJ transcripts_NNS between_IN 
        YL-_NNP 1_CD and_CC 
        TMOD_NNP 4_CD ,_, both_DT of_IN which_WDT theoretically_RB
        would_MD code_VB for_IN truncated_JJ versions_NNS of_IN YL-_NNP 1_CD ._. Intergenic_NNP
        splicing_VBG appears_VBZ to_TO be_VB a_DT rare_JJ event_NN :_: apparently_RB there_EX have_VBP
        been_VBN only_RB six_CD other_JJ cases_NNS reported_VBD in_IN mammals_NNS ._. Fears_NNS 
        et_CC ._. al_NN (_( 1996_CD )_) reported_VBD that_IN the_DT 
        Myelodysplasia_NNP syndrome_NN 1_CD (_( MDS_NNP 1_LS )_) gene_NN
        spliced_JJ into_IN exon_NN 2_CD of_IN the_DT adjacent_JJ 
        Ecotropic_NNP viral_JJ integration_NN site_NN
        1_CD (_( EVI_NNP 1_LS )_) gene_NN ,_, producing_VBG a_DT unique_JJ transcript_NN containing_VBG
        an_DT ORF_NNP that_WDT produces_VBZ a_DT GATA-binding_NNP transcriptional_NN
        activator_NN [_NN 30_CD 31_CD ]_NN ._. The_DT human_JJ 
        Galactose-_NNP 1_CD -_: phosphate_NN uridylytransferase_NN
        (_( GALT_NNP )_) gene_NN produces_VBZ an_DT intergenic_JJ transcript_NN by_IN
        skipping_VBG its_PRP$ last_JJ exon_NN and_CC splicing_VBG into_IN exon_NN 2_CD of_IN 
        Interleukin-_NNP 11_CD receptor_NN α-chain_JJ
        (_( IL-_NNP 11_CD Rα_NNP )_) [_NN 32_CD ]_NN ._. This_DT produces_VBZ an_DT intergenic_JJ
        transcript_NN that_WDT keeps_VBZ the_DT endogenous_JJ frame_NN of_IN both_DT genes_NNS ,_,
        thereby_RB coding_VBG for_IN a_DT theoretical_JJ protein_NN with_IN domains_NNS from_IN
        both_DT proteins_NNS ._. A_DT long_JJ terminal_NN repeat_NN from_IN a_DT human_JJ
        endogenous_JJ retrovirus_JJ (_( HERV_NNP )_) was_VBD shown_VBN to_TO drive_VB the_DT
        expression_NN of_IN an_DT intergenic_JJ transcript_NN from_IN an_DT unknown_JJ gene_NN
        named_VBD 
        HERV-HLTR_NNP associating_VBG 1_CD (_( HHLA_NNP 1_LS )_) and_CC
        human_JJ 
        otoconin-_NN 90_CD (_( OC_NNP 90_CD )_) to_TO produce_VB a_DT
        transcript_NN that_WDT is_VBZ highly_RB expressed_VBN in_IN teratocarcinoma_NN
        cells_NNS but_CC not_RB in_IN normal_JJ human_JJ tissues_NNS or_CC cell_NN lines_NNS [_NN 33_CD ]_NN
        ._. In_IN the_DT mouse_NN ,_, a_DT Prion-like_NNP downstream_JJ gene_NN named_VBD 
        doppel_NN (_( Dpl_NNP )_) was_VBD found_VBN to_TO have_VB an_DT
        intergenic_JJ transcript_NN that_WDT is_VBZ upregulated_JJ in_IN
        Prion-deficient_NNP mice_NNS [_NN 34_CD ]_NN ._. The_DT deletion_NN of_IN the_DT Prion_NNP
        gene_NN in_IN these_DT mice_NNS removes_VBZ the_DT splice_NN acceptor_NN site_NN of_IN exon_NN
        3_CD ,_, causing_VBG the_DT normal_JJ Prion_NNP transcript_NN to_TO skip_VB the_DT deleted_VBN
        exon_NN and_CC inadvertently_RB upregulate_NN the_DT normally_RB
        low-abundance_JJ intergenic_JJ transcript_NN by_IN forcing_VBG it_PRP to_TO splice_NN
        more_RBR often_RB to_TO the_DT 
        doppel_NN gene_NN ._. The_DT human_JJ cytochrome_NN
        P_NN 450_CD 2_CD C_NNP gene_NN cluster_NN maps_NNS to_TO chromosome_NN 10_CD q_NN 24_CD and_CC consists_VBZ
        of_IN four_CD genes_NNS which_WDT are_VBP composed_VBN of_IN nine_CD exons_NNS with_IN
        conserved_JJ exon_NN /_NN intron_NN boundaries_NNS ,_, and_CC have_VBP been_VBN shown_VBN to_TO
        produce_VB intergenic_JJ transcripts_NNS [_NN 35_CD 36_CD 37_CD 38_CD ]_NN ._. These_DT
        transcripts_NNS have_VBP been_VBN identified_VBN by_IN RT-PCR_NNP for_IN both_DT
        neighboring_VBG genes_NNS such_JJ as_IN CYP_NNP 2_CD C_NNP 18_CD and_CC CYP_NNP 2_CD C_NNP 19_CD ,_, as_RB well_RB as_IN
        CYP_NNP 2_CD C_NNP members_NNS separated_VBN by_IN another_DT gene_NN ,_, such_JJ as_IN CYP_NNP 2_CD C_NNP 18_CD
        and_CC CYP_NNP 2_CD C_NNP 8_CD [_NN 37_CD 38_CD ]_NN ._. The_DT latter_NN was_VBD shown_VBN by_IN RT-PCR_NNP to_TO
        include_VB exons_NNS from_IN both_DT genes_NNS consisting_VBG of_IN nine_CD exons_NNS and_CC
        therefore_RB could_MD code_VB for_IN a_DT chimeric_JJ CYP_NNP 2_CD C_NNP protein_NN [_NN 38_CD ]_NN ._.
        Recently_RB ,_, the_DT 
        Translin-associated_NNP factor_NN X_NNP gene_NN
        (_( TRAX_NNP )_) was_VBD demonstrated_VBN to_TO intergenically_RB splice_NN into_IN 
        Disrupted_NNP in_IN schizophrenia_NN gene_NN 1_CD
        (_( DISCI_NNP )_) [_NN 39_CD ]_NN ._. Several_JJ intergenic_JJ transcripts_NNS were_VBD
        described_VBN ,_, the_DT majority_NN of_IN which_WDT contain_VBP intervening_VBG
        non-coding_JJ exons_NNS that_WDT contain_VBP multiple_JJ stop_NN codons_NNS ._.
        At_IN least_JJS half_NN of_IN the_DT reported_VBN cases_NNS of_IN intergenic_JJ
        splicing_VBG result_NN from_IN skipping_VBG the_DT last_JJ exon_NN of_IN the_DT upstream_JJ
        gene_NN and_CC the_DT first_JJ exon_NN of_IN the_DT downstream_JJ gene_NN [_NN 32_CD 33_CD 39_CD ]_NN
        ._. This_DT is_VBZ thought_VBN to_TO be_VB due_JJ to_TO the_DT lack_NN of_IN donor_NN and_CC
        acceptor_NN splice_NN sites_NNS in_IN these_DT exons_NNS ,_, respectively_RB ._. For_IN 
        YL-_NNP 1_CD exon_NN 6_CD there_EX is_VBZ no_DT GT_NNP donor_NN site_NN
        at_IN the_DT end_NN of_IN the_DT exon_NN ,_, and_CC the_DT E_NNP 0_CD exon_NN of_IN 
        TMOD_NNP 4_CD contains_VBZ no_DT AG_NNP acceptor_NN ._. Thus_RB
        the_DT same_JJ pattern_NN seen_VBN in_IN the_DT other_JJ reported_VBD intergenic_JJ
        splicing_VBG events_NNS is_VBZ born_VBN out_IN in_IN our_PRP$ studies_NNS ._. This_DT idea_NN is_VBZ
        supported_VBN by_IN the_DT fact_NN that_IN we_PRP never_RB identified_VBD any_DT part_NN of_IN
        the_DT E_NNP 0_CD exon_NN in_IN our_PRP$ RACE_NNP products_NNS screened_VBD using_VBG the_DT 
        YL-_NNP 1_CD cDNA_NN ._. However_RB ,_, we_PRP did_VBD discover_VB
        this_DT product_NN when_WRB we_PRP rescreened_JJ our_PRP$ RACE_NNP products_NNS using_VBG a_DT
        5_CD '_POS 
        TMOD_NNP 4_CD probe_NN ._. Of_IN the_DT previously_RB
        reported_VBN cases_NNS ,_, the_DT closest_JJS distance_NN between_IN adjacent_JJ genes_NNS
        is_VBZ 4_CD kb_NN [_NN 32_CD ]_NN ._. 
        YL-_NNP 1_CD and_CC 
        TMOD_NNP 4_CD are_VBP separated_VBN by_IN 291_CD bp_NN ._. Since_IN
        this_DT genomic_JJ region_NN is_VBZ so_RB small_JJ ,_, it_PRP raises_VBZ the_DT question_NN as_IN
        to_TO the_DT location_NN of_IN the_DT 
        TMOD_NNP 4_CD promoter_NN ._. One_CD possibility_NN is_VBZ
        that_IN it_PRP lies_VBZ within_IN the_DT 1006_CD bp_NN between_IN the_DT E_NNP 0_CD exon_NN and_CC
        coding_VBG exon_NN 1_CD ,_, or_CC even_RB within_IN the_DT 291_CD bp_NN between_IN the_DT E_NNP 0_CD
        exon_NN and_CC 
        YL-_NNP 1_CD exon_NN 6_CD ._. A_DT more_RBR intriguing_JJ
        possibility_NN is_VBZ that_IN the_DT 
        TMOD_NNP 4_CD promoter_NN lies_VBZ further_JJ upstream_RB ,_,
        possibly_RB within_IN the_DT intronic_JJ structure_NN of_IN 
        YL-_NNP 1_CD ,_, or_CC as_IN a_DT shared_VBN promoter_NN with_IN 
        YL-_NNP 1_CD ._. 
        Whether_IN these_DT intergenic_JJ splice_NN products_NNS are_VBP
        biologically_RB relevant_JJ is_VBZ unclear_JJ ._. Due_JJ to_TO the_DT fact_NN that_IN the_DT
        size_NN of_IN the_DT transcripts_NNS for_IN 
        TMOD_NNP 4_CD and_CC 
        YL-_NNP 1_CD overlap_VB (_( 1_CD ._. 3_LS -_: 1_CD ._. 5_CD kb_NN )_) ,_, we_PRP
        cannot_NN demonstrate_VBP the_DT co-existence_NN of_IN these_DT intergenic_JJ
        variants_NNS by_IN Northern_NNP blot_NN analysis_NN ._. The_DT only_RB reported_VBN case_NN
        in_IN which_WDT an_DT intergenic_JJ transcript_NN has_VBZ been_VBN shown_VBN to_TO produce_VB
        a_DT functional_JJ protein_NN 
        in_IN vivo_NN is_VBZ the_DT case_NN of_IN MDS_NNP 1_CD /_NN EVI_NNP 1_CD [_NN 31_CD
        ]_NN ._. In_IN all_DT other_JJ cases_NNS ,_, the_DT intergenic_JJ transcript_NN or_CC the_DT
        theoretical_JJ protein_NN produced_VBN from_IN such_JJ transcripts_NNS has_VBZ been_VBN
        difficult_JJ to_TO demonstrate_VB by_IN Northern_NNP blot_NN analysis_NN ,_, and_CC
        none_NN have_VBP been_VBN shown_VBN by_IN Western_JJ analysis_NN in_IN normal_JJ tissues_NNS ._.
        However_RB ,_, all_DT of_IN these_DT transcripts_NNS have_VBP been_VBN identified_VBN by_IN
        RT-PCR_NNP and_CC some_DT by_IN RNase_NNP protection_NN assays_NNS ._. Thus_RB ,_, further_JJ
        analysis_NN will_MD be_VB needed_VBN to_TO determine_VB if_IN any_DT of_IN the_DT 
        YL-_NNP 1_CD /_NN TMOD_NNP 4_CD intergenic_JJ transcripts_NNS
        play_VBP an_DT important_JJ biological_JJ role_NN either_CC at_IN the_DT RNA_NNP or_CC
        protein_NN levels_NNS ._.
      
      
        Conclusion_NNP
        Through_IN our_PRP$ genomic_JJ analysis_NN we_PRP were_VBD able_JJ to_TO determine_VB
        that_IN 
        TMOD_NNP 2_CD and_CC 
        4_CD ,_, like_IN 
        TMOD_NNP 1_CD /_NN Tmod_NNP 1_CD ,_, share_NN conserved_JJ genomic_JJ
        structures_NNS consisting_VBG of_IN nine_CD coding_VBG exons_NNS and_CC a_DT single_JJ 5_CD '_POS
        UTR_NNP exon_NN (_( E_NNP 0_CD )_) ._. Using_VBG primers_NNS flanking_VBG the_DT coding_VBG exons_NNS of_IN 
        TMOD_NNP 2_CD we_PRP performed_VBD mutational_NN
        analysis_NN on_IN ALS_NNP 5_CD patients_NNS ._. No_DT mutations_NNS or_CC polymorphisms_NNS
        were_VBD detected_VBN ,_, but_CC our_PRP$ primer_NN pairs_NNS and_CC reaction_NN conditions_NNS
        may_MD prove_VB useful_JJ for_IN future_JJ mutational_NN analyses_NNS ._. We_PRP
        determined_VBD that_IN 
        YL-_NNP 1_CD comprises_VBZ six_CD exons_NNS ,_, and_CC its_PRP$
        last_JJ exon_NN lies_VBZ 291_CD bp_NN from_IN 
        TMOD_NNP 4_CD ._. We_PRP also_RB identified_VBD six_CD ESTs_NNP
        that_DT show_NN nonconventional_NN splicing_VBG ._. Intergenic_NNP splice_NN
        products_NNS between_IN 
        YL-_NNP 1_CD and_CC 
        TMOD_NNP 4_CD were_VBD identified_VBN in_IN the_DT EST_NNP
        database_NN ,_, by_IN 5_CD '_POS RACE_NNP ,_, and_CC by_IN RT-PCR_NNP ._. Although_IN we_PRP did_VBD not_RB
        determine_VB whether_IN this_DT relationship_NN between_IN 
        YL-_NNP 1_CD and_CC 
        TMOD_NNP 4_CD is_VBZ conserved_JJ in_IN the_DT mouse_NN ,_, it_PRP
        may_MD be_VB an_DT important_JJ possibility_NN to_TO consider_VB when_WRB devising_VBG
        strategies_NNS for_IN targeted_VBN deletion_NN not_RB only_RB of_IN 
        YL-_NNP 1_CD or_CC 
        TMOD_NNP 4_CD but_CC any_DT gene_NN pair_NN in_IN which_WDT
        intergenic_JJ splicing_VBG occurs_VBZ ._. This_DT is_VBZ clearly_RB illustrated_VBN by_IN
        the_DT Prion_NNP deficient_NN mice_NNS produced_VBN by_IN Sakaguchi_NNP et_CC ._. al_NN
        (_( 1996_CD )_) and_CC Moore_NNP (_( 1997_CD )_) ._. In_IN these_DT animals_NNS exon_NN 3_CD and_CC its_PRP$
        splice_NN acceptor_NN were_VBD deleted_VBN ,_, causing_VBG a_DT rare_JJ intergenic_JJ
        transcript_NN between_IN 
        Prion_NNP and_CC 
        Doppel_NNP to_TO be_VB highly_RB upregulated_JJ and_CC
        abnormally_RB expressed_VBD in_IN the_DT brain_NN ,_, leading_VBG to_TO late-onset_JJ
        ataxia_NN and_CC Purkinje_NNP cell_NN degeneration_NN [_NN 34_CD ]_NN ._.
        The_DT recent_JJ completion_NN of_IN the_DT human_JJ genome_NN by_IN Ventner_NNP 
        et_CC ._. al_NN (_( 2001_CD )_) has_VBZ led_VBN to_TO the_DT new_JJ
        prediction_NN that_IN the_DT human_JJ genome_NN contains_VBZ only_RB ~_NN 30_CD ,_, 000_CD
        genes_NNS ,_, significantly_RB lower_JJR than_IN previous_JJ estimates_NNS of_IN
        ~_NN 100_CD ,_, 000_CD genes_NNS [_NN 40_CD ]_NN ._. This_DT estimate_NN does_VBZ not_RB ,_, however_RB ,_,
        include_VBP the_DT possibility_NN of_IN additional_JJ proteins_NNS encoded_JJ by_IN
        alternative_NN or_CC intergenic_JJ transcripts_NNS ._. The_DT genomic_JJ
        organization_NN between_IN 
        YL-_NNP 1_CD and_CC 
        TMOD_NNP 4_CD clearly_RB raises_VBZ the_DT possibility_NN
        of_IN additional_JJ proteins_NNS being_VBG produced_VBN from_IN intergenic_JJ
        transcripts_NNS ._. In_IN addition_NN ,_, it_PRP highlights_VBZ the_DT difficulties_NNS
        that_WDT may_MD arise_VB when_WRB trying_VBG to_TO understand_VB gene_NN regulation_NN
        for_IN genes_NNS that_WDT lie_VBP extremely_RB close_RB to_TO one_CD another_DT or_CC that_DT
        form_NN intergenic_JJ transcripts_NNS ._. 
        YL-_NNP 1_CD 's_POS intraexonic_JJ splicing_VBG
        illustrates_VBZ yet_RB another_DT level_NN of_IN genomic_JJ complexity_NN in_IN that_DT
        alternative_JJ transcripts_NNS could_MD be_VB produced_VBN from_IN the_DT use_NN of_IN
        non-canonical_JJ splice_NN sites_NNS that_WDT lie_VBP even_RB within_IN an_DT
        individual_JJ exon_NN ._. This_DT ,_, in_IN conjunction_NN with_IN intergenic_JJ
        splicing_VBG ,_, may_MD significantly_RB increase_VB the_DT number_NN of_IN
        predicted_VBD proteins_NNS encoded_JJ by_IN the_DT human_JJ genome_NN and_CC will_MD
        certainly_RB pose_VB a_DT challenge_NN for_IN anyone_NN trying_VBG to_TO decipher_NN
        genomic_JJ organization_NN and_CC regulation_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Genomic_NNP organization_NN and_CC sequence_NN analysis_NN of_IN
          TMOD_NNP 2_CD ,_, TMOD_NNP 4_CD ,_, and_CC YL-_NNP 1_CD
          The_DT genomic_JJ organization_NN of_IN each_DT gene_NN was_VBD determined_VBN
          using_VBG two_CD methods_NNS ._. The_DT first_JJ involved_VBN PCR_NNP amplification_NN
          from_IN either_DT PAC_NNP 61_CD J_NNP 10_CD (_( for_IN 
          TMOD_NNP 2_LS )_) or_CC BAC_NNP HB_NNP 342_CD I_PRP 3_CD (_( for_IN 
          TMOD_NNP 4_CD and_CC 
          YL-_NNP 1_LS )_) using_VBG primers_NNS within_IN each_DT
          exon_NN to_TO amplify_VB the_DT exon_NN and_CC the_DT intervening_VBG intron_NN and_CC
          use_VB it_PRP as_IN a_DT substrate_NN for_IN sequencing_VBG the_DT exon-intron_JJ
          boundaries_NNS ._. We_PRP also_RB digested_VBN PAC_NNP 61_CD J_NNP 10_CD (_( from_IN the_DT RPCI-_NNP 1_CD
          human_JJ PAC_NNP library_NN ,_, Roswell_NNP Park_NNP Cancer_NNP Institute_NNP )_) and_CC BAC_NNP
          HB_NNP 342_CD I_PRP 3_CD (_( from_IN the_DT human_JJ CITB_NNP BAC_NNP library_NN ._. Research_NNP
          Genetics_NNP ,_, Inc_NNP ._. )_) with_IN RSAI_NNP and_CC then_RB subcloned_JJ the_DT DNA_NNP
          fragments_NNS into_IN pZero_NN 2_CD ._. 0_CD according_VBG to_TO the_DT manufacturer_NN 's_POS
          instructions_NNS ._. We_PRP screened_VBD colonies_NNS by_IN hybridization_NN using_VBG
          the_DT cDNA_NN for_IN each_DT gene_NN as_IN a_DT probe_NN ._. All_DT labeling_VBG reactions_NNS
          for_IN all_DT procedures_NNS were_VBD performed_VBN using_VBG the_DT Megaprime_NNP DNA_NNP
          labeling_VBG system_NN (_( Amersham_NNP Pharmacia_NNP Biotech_NNP ,_, Piscataway_NNP ,_,
          NJ_NNP )_) ._. Positive_JJ colonies_NNS were_VBD isolated_VBN and_CC sequenced_JJ using_VBG
          a_DT PRISM_NNP BigDye_NNP Terminator_NNP Cycle_NNP sequencing_VBG kit_NN and_CC an_DT ABI_NNP
          3700_CD automated_VBN DNA_NNP sequencer_NN (_( Perkin-_NNP Elmer_NNP Applied_NNP
          Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) ._.
        
        
          Mutational_NNP Analysis_NNP of_IN TMOD_NNP 2_CD for_IN ALS_NNP 5_CD and_CC TMOD_NNP 4_CD for_IN
          LGMD_NNP 1_CD B_NNP
          The_DT coding_VBG exons_NNS of_IN 
          TMOD_NNP 2_CD and_CC 
          TMOD_NNP 4_CD were_VBD amplified_VBN from_IN patient_NN
          lymphoblast_NN genomic_JJ DNA_NNP using_VBG primers_NNS flanking_VBG the_DT exon_NN
          (_( Table_NNP 2_LS )_) ._. Reaction_NNP conditions_NNS were_VBD as_IN follows_VBZ for_IN a_DT 50_CD
          μl_NN PCR_NNP reaction_NN :_: Perkin-_NNP Elmer_NNP Cetus_NNP PCR_NNP buffer_NN ;_: 1_CD ._. 5_CD mM_NN
          MgCl_NNP 
          2_CD ,_, 0_CD ._. 25_CD mM_NN dNTPs_NNS ,_, 1_CD ._. 5_CD μl_NN of_IN each_DT
          primer_NN (_( 10_CD μM_NN )_) ,_, 1_CD %_NN DMSO_NNP ,_, 5_CD U_NNP of_IN Taq_NNP polymerase_NN (_( Life_NNP
          Technologies_NNPS )_) ._. Thermocycler_NNP conditions_NNS were_VBD as_IN follows_VBZ
          for_IN a_DT Perkin_NNP Elmer_NNP 9600_CD thermocycler_NN :_: 94_CD °_NN C_NNP for_IN 4_CD min_NN ,_,
          followed_VBN by_IN 35_CD cycles_NNS of_IN 94_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_, annealing_VBG
          temperature_NN (_( see_VB Table_NNP 2_LS )_) for_IN 30_CD s_VBZ ,_, 72_CD °_NN C_NNP for_IN 1_CD min_NN ,_, and_CC a_DT
          final_JJ extension_NN of_IN 72_CD °_NN C_NNP for_IN 10_CD min_NN ._. The_DT resulting_VBG PCR_NNP
          products_NNS were_VBD subjected_VBN to_TO agarose_NN gel_NN electrophoresis_NNS
          and_CC the_DT DNA_NNP was_VBD recovered_VBN from_IN excised_VBD bands_NNS using_VBG the_DT
          Qiagen_NNP Quick_NNP Gel_NNP Extraction_NNP Kit_NNP (_( CAT_NNP #_# 28706_CD )_) ._. Each_DT PCR_NNP
          product_NN was_VBD then_RB sequenced_JJ ._.
        
        
          5_LS '_POS and_CC 3_CD '_POS Rapid_NNP Amplification_NNP of_IN cDNA_NN ends_VBZ for_IN
          TMOD_NNP 4_CD
          We_PRP used_VBD Clontech_NNP 's_POS Human_NNP Heart_NNP Marathon-_NNP Ready_JJ cDNA_NN
          (_( Cat_NNP #_# 7404_CD -_: 1_LS )_) to_TO perform_VB 5_CD '_POS and_CC 3_CD '_POS RACE_NNP to_TO the_DT 
          TMOD_NNP 4_CD gene_NN ._. Nested_NNP primers_NNS were_VBD
          designed_VBN within_IN exon_NN 9_CD and_CC exon_NN 2_CD of_IN 
          TMOD_NNP 4_CD ,_, TMOD_NNP 4_CD EX_NNP 9_CD RACE_NNP 5_CD '_'' ._. 1_LS
          5_CD '_POS TACAGGAAAGGAGGACAGATGAGG_NNP 3_CD '_POS ,_, and_CC TMOD_NNP 4_CD EX_NNP 9_CD RACE_NNP 5_CD '_'' ._. 2_LS
          5_CD '_POS GATTTAAGTGTCCAGTGCTCCCAG_NNP 3_CD '_POS ,_, and_CC TMOD_NNP 4_CD EX_NNP 2_CD RACE_NNP 5_CD '_'' ._. 1_LS
          5_CD '_POS GGGCACCAAGTCATCACGCTCT_NNP 3_CD '_POS ,_, TMOD_NNP 4_CD EX_NNP 2_CD RACE_NNP 5_CD '_POS ._. 2_CD
          5_CD '_POS CCAAGTACTGCAAAAGGGCCTC_NNP 3_CD '_POS ,_, TMOD_NNP 4_CD EX_NNP 2_CD RACE_NNP 3_CD '_'' ._. 1_LS
          5_CD '_POS GGACTAAGACAACGTGACCAGACA_NNP 3_CD '_POS ,_, and_CC TMOD_NNP 4_CD EX_NNP 2_CD RACE_NNP 3_CD '_POS ._. 2_CD
          5_CD '_POS GAGGCCCTTTTGCAGTACTTGG_NNP 3_CD '_'' ._. The_DT initial_JJ RACE_NNP reaction_NN to_TO
          identify_VB intergenic_JJ RACE_NNP products_NNS was_VBD performed_VBN using_VBG the_DT
          gene_NN specific_JJ primer_NN ,_, TMOD_NNP 4_CD RACE_NNP 5_CD '_'' ._. 1_LS ,_, and_CC Clontech_NNP 's_POS AP_NNP 1_CD
          primer_NN in_IN a_DT 50_CD μl_NN reaction_NN using_VBG the_DT Roche_NNP High_NNP Fidelity_NNP
          Kit_NNP (_( CAT_NNP #_# 1_CD -_: 732_CD -_: 641_CD )_) ._. Thermocycler_NNP conditions_NNS for_IN a_DT
          PE_NNP 9600_CD were_VBD as_IN follows_VBZ :_: 94_CD °_NN C_NNP for_IN 5_CD min_NN ,_, followed_VBN by_IN 10_CD
          cycles_NNS of_IN 94_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_, 71_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_, 72_CD °_NN C_NNP for_IN 4_CD min_NN ;_:
          followed_VBN by_IN one_CD cycle_NN of_IN 94_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_, 68_CD °_NN C_NNP for_IN 4_CD min_NN 20_CD
          s_VBZ ,_, followed_VBN by_IN 17_CD additional_JJ cycles_NNS each_DT adding_VBG 20_CD s_VBZ to_TO
          each_DT extension_NN ;_: final_JJ extension_NN at_IN 72_CD °_NN C_NNP for_IN 10_CD min_NN ._. 5_CD μl_NN
          of_IN a_DT 1_CD :_: 50_CD dilution_NN of_IN the_DT product_NN from_IN the_DT first_JJ RACE_NNP
          reaction_NN served_VBD as_IN template_NN for_IN the_DT second_JJ nested_JJ RACE_NNP
          reaction_NN ._. Reaction_NNP and_CC thermocycler_NN conditions_NNS were_VBD the_DT
          same_JJ as_IN before_IN except_IN gene_NN specific_JJ primer_NN 2_CD ,_,
          TMOD_NNP 4_CD RACE_NNP 5_CD '_'' ._. 2_LS ,_, and_CC Clontech_NNP 's_POS AP_NNP 2_CD primer_NN were_VBD used_VBN ._. RACE_NNP
          products_NNS were_VBD then_RB subcloned_JJ into_IN pbluescript_NN KS_NNP II_NNP
          +_NN using_VBG TA_NNP vector_NN cloning_VBG ._. Positive_JJ products_NNS were_VBD then_RB
          identified_VBN by_IN colony_NN hybridization_NN using_VBG the_DT 
          YL-_NNP 1_CD cDNA_NN as_IN a_DT probe_NN ._. A_DT secondary_JJ
          screening_NN was_VBD then_RB performed_VBN using_VBG exon_NN 2_CD primers_NNS
          TMOD_NNP 4_CD EX_NNP 2_CD RACE_NNP 5_CD '_'' ._. 1_LS ,_, followed_VBN by_IN a_DT second_JJ round_NN of_IN race_NN
          using_VBG TMOD_NNP 4_CD EX_NNP 2_CD RACE_NNP 5_CD '_'' ._. 2_LS ._. Likewise_RB the_DT 3_CD '_POS RACE_NNP was_VBD
          performed_VBN using_VBG TMOD_NNP 4_CD EX_NNP 2_CD RACE_NNP 3_CD '_'' ._. 1_LS ,_, followed_VBN by_IN
          TMOD_NNP 4_CD EX_NNP 2_CD RACE_NNP 3_CD '_'' ._. 2_LS ._. RACE_NNP products_NNS were_VBD then_RB subcloned_JJ and_CC
          identified_VBN by_IN using_VBG either_DT a_DT 5_CD '_POS or_CC 3_CD '_POS probes_NNS made_VBN from_IN
          the_DT 
          TMOD_NNP 4_CD cDNA_NN ._. Positive_JJ RACE_NNP products_NNS
          were_VBD sequenced_JJ ._.
        
        
          RT-PCR_NNP of_IN YL-_NNP 1_CD and_CC Expression_NNP Analysis_NNP of_IN
          YL-_NNP 1_CD
          For_IN RT-PCR_NNP of_IN 
          YL-_NNP 1_CD ,_, we_PRP performed_VBD the_DT same_JJ
          procedure_NN as_IN described_VBN in_IN Cox_NNP and_CC Zoghbi_NNP (_( 2000_CD )_) ._.
          Exceptions_NNP were_VBD the_DT RNA_NNP source_NN ,_, human_JJ heart_NN poly_RB (_( A_DT )_) +_NN
          RNA_NNP ,_, (_( Clontech_NNP ,_, 6533_CD -_: 1_LS )_) ,_, primers_NNS were_VBD YL_NNP 1_CD -_: 35_CD ,_,
          GTAGGCGGTATGAGTTTG_NNP ,_, and_CC YL_NNP 1_CD -_: 1277_CD ,_, AAAACACAACGAAACCTG_NNP ,_,
          respectively_RB ,_, and_CC the_DT annealing_VBG temperature_NN was_VBD 53_CD °_NN C_NNP ._. The_DT
          resulting_VBG RT-PCR_NNP product_NN was_VBD subcloned_JJ using_VBG TA_NNP cloning_VBG
          into_IN pbluescript_NN KSII_NNP +_NN ._. This_DT product_NN was_VBD then_RB sequenced_JJ
          to_TO confirm_VB that_IN it_PRP matched_VBD the_DT reported_VBN cDNA_NN ._. We_PRP examined_VBD
          the_DT expression_NN pattern_NN of_IN 
          YL-_NNP 1_CD using_VBG this_DT RT-PCR_NNP product_NN as_IN a_DT
          probe_NN on_IN a_DT Clontech_NNP Human_NNP multiple_JJ tissue_NN Northern_NNP blot_NN
          (_( CAT_NNP #_# #_# 7760_CD -_: 1_LS )_) ._.
        
      
    
  
